A novel MGB probe-based assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPMI (nucleophosmin) exon 12 mutations

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	DVOŘÁKOVÁ Dana OHLÍDALOVÁ D. POSPÍŠILOVÁ J. LENGEROVÁ Martina MAYER Jiří
Year of publication	2008
Type	Conference abstract
MU Faculty or unit	Faculty of Medicine
Citation
Description	Insertions into exon 12 of NPM1 gene represent the most frequent molecular aberration in the subgroup of patients with AML otherwise showing normal karyotype. Therefore, NPM1 mutations may be used as a marker for quantification of minimal residual disease (MRD). Here we propose highly sensitive and reproducible MGB probe-based method for MRD.
Related projects:	Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies